Enhancement of drug delivery to bone: Characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide

Molecular Genetics and Metabolism

Volumn 88, Issue 3, 2006, Pages 244-255

  Nishioka, Tatsuo ^a,b   Tomatsu, Shunji ^a   Gutierrez, Monica A ^a   Miyamoto, Ken ichi ^b   Trandafirescu, Georgeta G ^a   Lopez, Patricia L C ^a   Grubb, Jeffrey H ^a   Kanai, Rie ^c   Kobayashi, Hironori ^c   Yamaguchi, Seiji ^c   Gottesman, Gary S ^a   Cahill, Richard ^a   Noguchi, Akihiko ^a   Sly, William S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

Author keywords

Alkaline phosphatase; Drug delivery system; Hypophosphatasia

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTIC ACID; CARBOHYDRATE; HYDROXYAPATITE; LECTIN; OLIGOPEPTIDE; PYROPHOSPHATE;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; BONE; BONE MARROW; BONE MINERALIZATION; CARBOXY TERMINAL SEQUENCE; CHO CELL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; ENZYME REPLACEMENT; FLUORESCENCE; HUMAN; HUMAN CELL; HYPOPHOSPHATASIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FOLDING; PURIFICATION; STRUCTURE ANALYSIS;

ALKALINE PHOSPHATASE; ANIMALS; ASPARAGINE; BONE MARROW CELLS; CALCIFICATION, PHYSIOLOGIC; CELLS, CULTURED; CRICETINAE; CRICETULUS; DURAPATITE; HUMANS; HYPOPHOSPHATASIA; INFANT; LIVER; MICE; OLIGOPEPTIDES; TISSUE DISTRIBUTION;

CRICETULUS GRISEUS;

EID: 33745497185     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.02.012     Document Type: Article

References (63)

1. Fraser D. Hypophosphatasia. Am. J. Med. 22 (1957) 730-746
2. Whyte M.P. Hypophosphatasia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 5313-5329
3. Silver M.M., Vilos G.A., and Milne K.J. Pulmonary hypophosphatasia in neonatal hypophosphatasia. Pediatr. Pathol. 8 (1988) 483-493
4. Ali S.Y. Matrix formation and mineralization in bone. In: Whitehead C.C. (Ed). Bone Biology and Skeletal Disorders (1992), Carfax Publishing Co., Abingdon, UK 19-38
5. Anderson H.C. Molecular biology of matrix vesicles. Clin. Orthop. Relat. Res. 314 (1995) 266-280
6. Boskey A.L., Boyan B.D., and Schwartz Z. Matrix vesicles promote mineralization in a gelatin gel. Calcif. Tissue Int. 60 (1997) 309-315
7. Boskey A.L. Amorphous calcium phosphate: the contention of bone. J. Dent. Res. 76 (1997) 1433-1436
8. Anderson H.C. Mechanisms of pathologic calcification. Rheum. Dis. Clin. North Am. 14 (1988) 303-319
9. Bonewald L.F., Schwartz Z., Swain L.D., and Boyan B.D. Stimulation of matrix vesicle enzyme activity in osteoblast-like cells by 1,25(OH)2D3 and transforming growth factor beta (TGFβ). Bone Miner. 17 (1992) 139-144
10. Fedde K.N. Human osteosarcoma cells spontaneously release matrix-vesicle-like structures with the capacity to mineralize. Bone Miner. 17 (1992) 145-151
11. Fleisch H., Russell R.G., and Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212 (1966) 901-903
12. de Jong A.S., Hak T.J., and van Duijn P. The dynamics of calcium phosphate precipitation studied with a new polyacrylamide steady state matrix-model: influence of pyrophosphate collagen and chondroitin sulfate. Connect. Tissue Res. 7 (1980) 73-79
13. Meyer J.L. Can biological calcification occur in the presence of pyrophosphate?. Arch. Biochem. Biophys. 15 (1984) 1-8
14. Moss D.W., Eaton R.H., Smith J.K., and Whitby L.G. Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem. J. 102 (1967) 53-57
15. Leon F.A., Rezende L.A., Ciancaglini P., and Pizauro J.M. Allosteric modulation of pyrophosphatase activity of rat osseous plate alkaline phosphatase by magnesium ions. Int. J. Biochem. Cell Biol. 30 (1998) 89-97
16. Russell R.G., Bisaz S., Donath A., Morgan D.B., and Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J. Clin. Invest. 50 (1971) 961-965
17. Sorensen E., and Flodgaard H. Adult hypophosphatasia. Acta Med. Scand. 197 (1975) 357-360
18. Sorensen S.A., Flodgaard H., and Sorensen E. Serum alkaline phosphatase, serum pyrophosphatase, phosphorylethanolamine and inorganic pyrophosphate in plasma and urine. A genetic and clinical study of hypophosphatasia. Monogr. Hum. Genet. 10 (1978) 66-69
19. Anderson H.C. Pyrophosphate stimulation of calcium uptake into cultured embryonic bones. Fine structure of matrix vesicles and their role in calcification. Dev. Biol. 34 (1973) 211-227
20. Anderson H.C., Hsu H.H., Morris D.C., Fedde K.N., and Whyte M.P. Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am. J. Pathol. 151 (1997) 1555-1561
21. Anderson H.C., Sipe J.B., Hessle L., Dhanyamraju R., Atti E., Camacho N.P., and Millan J.L. Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am. J. Pathol. 164 (2004) 841-847
22. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
23. Sands M.S., Vogler C., Kyle J.W., Grubb J.H., Levy B., Galvin N., Sly W.S., and Birkenmeier E.H. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J. Clin. Invest. 93 (1994) 2324-2331
24. Shull R.M., Kakkis E.D., McEntee M.F., Kania S.A., Jonas A.J., and Neufeld E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. USA 91 (1994) 12937-12941
25. Crawley A.C., Brooks D.A., Muller V.J., Petersen B.A., Isaac E.L., Bielicki J., King B.M., Boulter C.D., Moore A.J., Fazzalari N.L., Anson D.S., Byers S., and Hopwood J.J. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest. 97 (1996) 1864-1873
26. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188
27. Altarescu G., Hill S., Wiggs E., Jeffries N., Kreps C., Parker C.C., Brady R.O., Barton N.W., and Schiffmann R. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr. 138 (2001) 539-547
28. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. International collaborative Fabry disease study group, safety and efficacy of recombinant human α-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 345 (2001) 9-16
29. Furbish F.S., Steer C.J., Krett N.L., and Barranger J.A. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta 673 (1981) 425-434
30. Murray G.J. Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells. Methods Enzymol. 149 (1987) 25-42
31. Stahl P.D., Rodman J.S., Miller M.J., and Schlesinger P.H. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and glycosidases by alveolar macrophages. Proc. Natl. Acad. Sci. USA 75 (1978) 1399-1403
32. Achord D.T., Brot F.E., Bell C.E., and Sly W.S. Human β-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 (1978) 269-278
33. Barranger J.A., and O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. 24 (2001) 89-96
34. LeBowitz J.H., Grubb J.H., Maga J.A., Schmiel D.H., Vogler C., and Sly W.S. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA 101 (2004) 3083-3088
35. Orii K.O., Grubb J.H., Vogler C., Levy B., Tan Y., Markova K., Davidson B.L., Mao Q., Orii T., Kondo N., and Sly W.S. Defining the pathway for Tat-mediated delivery of β-glucuronidase in cultured cells and MPS VII mice. Mol. Ther. 12 (2005) 345-352
36. Whyte M.P., Valdes R., Ryan L.M., and McAlister W.H. Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J. Pediatr. 101 (1982) 379-386
37. Whyte M.P., McAlister W.H., Patton L.S., Magill H.L., Fallon M.D., Lorentz W.B., and Herrod H.G. Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. J. Pediatr. 105 (1984) 926-933
38. Whyte M.P., Magill H.L., Fallon M.D., and Herrod H.G. Infantile hypophosphatasia: normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase. J. Pediatr. 108 (1986) 82-88
39. Weninger M., Stinson R.A., Plenk H., Böck P., and Pollak A. Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr. Scand. Suppl. 360 (1989) 154-160
40. Whyte M.P., Landt M., Ryan L.M., Mulivor R.A., Henthorn P.S., Fedde K.N., Mahuren J.D., and Coburn S.P. Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphatem and pyridoxal 5′-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J. Clin. Invest. 95 (1995) 1440-1445
41. Murshed M., Harmey D., Millan J.L., McKee M.D., and Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 19 (2005) 1093-1104
42. Kasugai S., Fujisawa R., Waki Y., Miyamoto K., and Ohya K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J. Bone Miner. Res. 15 (2000) 936-943
43. Yokogawa K., Miya K., Sekido T., Higashi Y., Nomura M., Fujisawa R., Morito K., Masamune Y., Waki Y., Kasugai S., and Miyamoto K. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142 (2001) 1228-1233
44. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 15 (1991) 193-199
45. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
46. Merril C.R., Goldman D., and Van Keuren M.L. Silver staining methods for polyacrylamide gel electrophoresis. Methods Enzymol. 96 (1983) 230-239
47. Koyama I., Sakagishi Y., and Komoda Y.T. Different lectin affinities in rat alkaline phosphatase isozymes: multiple forms of the isozyme isolated by heterogeneities of sugar moieties. J. Chromatogr. 374 (1986) 51-59
48. Mcgee-Russell S.M. Histochemical methods for calcium. J. Histochem. Cytochem. 6 (1958) 22-42
49. Di Mauro S., Manes T., Hessle L., Kozlenkov A., Pizauro J.M., Hoylaerts M.F., and Millan J.L. Kinetic characterization of hypophosphatasia mutations with physiological substrates. J. Bone Miner. Res. 17 (2002) 1383-1391
50. Komoda T., and Sakagishi Y. The function of carbohydrate moiety and alteration of carbohydrate composition in human alkaline phosphatase isoenzymes. Biochim. Biophys. Acta 523 (1978) 395-406
51. Walton R.J., Preston C.J., Russell R.G., and Kanis J.A. An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease. Clin. Chim. Acta 63 (1975) 227-229
52. Clubb J.S., Neale F.C., and Posen S. The behavior of infused human placental alkaline phosphatase in human subjects. J. Lab. Clin. Med. 66 (1965) 493-507
53. Bhavanandan V.P., and Katlic A.W. The interaction of wheat germ agglutinin with sialoglycoproteins. The role of sialic acid. J. Biol. Chem. 254 (1979) 4000-4008
54. Gallagher J.T., Morris A., and Dexter T.M. Identification of two binding sites for wheat-germ agglutinin on polylactosamine-type oligosaccharides. Biochem. J. 231 (1985) 115-122
55. Magnusson P., and Farley J.R. Differences in sialic acid residues among bone alkaline phosphatase isoforms: a physical, biochemical, and immunological characterization. Calcif. Tissue Int. 71 (2002) 508-518
56. Van den Hout J.M., Kamphoven J.H., Winkel L.P., Arts W.F., De Klerk J.B., Loonen M.C., Vulto A.G., Cromme-Dijkhuis A., Weisglas-Kuperus N., Hop W., Van Hirtum H., Van Diggelen O.P., Boer M., Kroos M.A., Van Doorn P.A., Van der Voort E., Sibbles B., Van Corven E.J., Brakenhoff J.P., Van Hove J., Smeitink J.A., de Jong G., Reuser A.J., and Van der Ploeg A.T. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics 113 (2004) e448-e457
57. Butler W.T. The nature and significance of osteopontin. Connect. Tissue Res. 23 (1989) 123-136
58. Fujisaki J., Tokunaga Y., Takahashi T., Shimojo F., Kimura S., and Hata T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. iv effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J. Drug Target. 5 (1998) 129-138
59. Oldberg A., Franzen A., and Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl. Acad. Sci. USA 83 (1986) 8819-8823
60. Nagata T., Bellows C.G., Kasugai S., Butler W.T., and Sodek J. Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem. J. 274 (1991) 513-520
61. Sekido T., Sakura N., Higashi Y., Miya K., Nitta Y., Nomura M., Sawanishi H., Morito K., Masamune Y., Kasugai S., Yokogawa K., and Miyamoto K. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J. Drug Target. 9 (2001) 111-121
62. Waymire K.G., Mahuren J.D., Jaje J.M., Guilarte T.R., Coburn S.P., and MacGregor G.R. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nat. Genet. 11 (1995) 45-51
63. Narisawa S., Frohlander N., and Millan J.L. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev. Dyn. 208 (1997) 432-446